TGFB1 and familial dilated cardiomyopathy: IGFBP2 may promote the conversion of endothelial cells to mesenchymal cells through TGF-β signaling, thus aggravating cardiac fibrosis progression, which negatively affects the prognoses and left ventricular functions of DCM patients.